Related Experiment Video
Updated: Jul 2, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA
Stephen C Becker1, Juli Foster-Frey, David M Donovan
1Animal Biosciences and Biotechnology Laboratory, Animal and Natural Resources Institute, Agricultural Research Service-U.S. Department of Agriculture, Beltsville Agricultural Research Center, 10300 Baltimore Avenue, Beltsville, MD 20705, USA.
Abstract:
LysK is the endolysin from the staphylococcal bacteriophage K, and can digest the cell wall of many staphylococci. Lysostaphin is a bacteriocin secreted by Staphylococcus simulans to kill Staphylococcus aureus. Both LysK and lysostaphin have been shown to lyse methicillin-resistant S. aureus (MRSA). This study describes optimal reaction conditions for the recombinant His-tagged LysK protein (pH range pH 6-10, and 0.3-0.5 M NaCl), and C-His-LysK MIC (32.85+/-4.87 mug mL(-1)). LysK and lysostaphin demonstrate antimicrobial synergy by the checkerboard assay.
Insights
LysK and lysostaphin are potent antimicrobial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). Optimal conditions for LysK were identified, and the study found these agents work synergistically to combat MRSA infections.
Area of Science:
- Microbiology
- Biochemistry
- Antimicrobial Research
Background:
- Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), poses a significant public health threat.
- Bacteriophage endolysins like LysK and bacteriocins like lysostaphin are promising alternatives to conventional antibiotics.
- Previous research indicated that both LysK and lysostaphin can lyse MRSA cells.
Purpose of the Study:
- To determine the optimal reaction conditions for recombinant His-tagged LysK protein activity.
- To establish the minimum inhibitory concentration (MIC) of C-His-LysK.
- To investigate the potential synergistic antimicrobial activity between LysK and lysostaphin against MRSA.
Main Methods:
- Recombinant His-tagged LysK protein was purified and its enzymatic activity was assessed under varying pH and NaCl concentrations.
- The minimum inhibitory concentration (MIC) of C-His-LysK was determined using standard microbiological assays.
- A checkerboard assay was employed to evaluate the synergistic antimicrobial effects of LysK and lysostaphin in combination.
Main Results:
- Optimal activity for recombinant His-tagged LysK was observed within a pH range of 6-10 and a NaCl concentration of 0.3-0.5 M.
- The MIC of C-His-LysK was determined to be 32.85 ± 4.87 µg/mL.
- The checkerboard assay demonstrated a synergistic antimicrobial effect when LysK and lysostaphin were used in combination against MRSA.
Conclusions:
- LysK exhibits optimal enzymatic activity under specific biochemical conditions (pH 6-10, 0.3-0.5 M NaCl).
- LysK and lysostaphin exhibit significant antimicrobial synergy, offering a potential strategy for enhanced MRSA treatment.
- The findings support the development of LysK and lysostaphin as a dual-action therapeutic approach against MRSA infections.
More Related Videos
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Lytic Cycle of Bacteriophages
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Mechanism of Antibiotic Resistance in MRSA
Lysogenic Cycle of Bacteriophages
DNA Bacteriophages

